Too many middlemen disconnects you from patients.

See How Close
Lost in Transition Telephones
Lost in Transition

Treating rare disease shouldn’t be like a bad game of telephone, with each step generating chaos and confusion. Patient adherence suffers, quality of care diminishes, manufacturers miss out on vital feedback and cost goes up. But imagine if you could cut past all that. We did.

Learn More


Learn what's happening in the world of Dohmen and our clients
October 24, 2016

Dohmen launches new Market Access and Government Program services to help clients maximize revenue and simplify commercial operations

Dohmen Life Science Services is expanding its financial service offerings to now include Market Access and Government Programs. The new services complement the company’s broad capabilities from supply chain and compliance services to patient services and technology.
learn more
October 14, 2016

Dohmen’s patient-centered care model for rare disease featured in PharmaVOICE

PharmaVOICE’s October issue dives deeper into the unique needs of the rare disease patient community and why new care models are driving better financial and clinical outcomes. The article, “Creating a More Efficient, Effective and Easier Model for Patient Care” showcases how empowered patients are calling for a shift away from multi-vendor, disconnected operations, including pharmacy benefit managers, wholesalers, specialty pharmacies and other “hub” service companies
learn more
October 04, 2016

Dohmen leaders shine light on regulatory strategy and technology innovation at BioForward Summit

Wisconsin’s life sciences sector took center stage in Madison, as leaders in the bioscience, manufacturing, medical device and IT industries gathered for the 2016 Wisconsin BioHealth Summit. Keynote speakers and industry panels, organized by BioForward, showcased that Wisconsin is quickly becoming a leader in integrated health solutions.
learn more
October 04, 2016

Dohmen showcases rare disease patient support at Global Genes Summit

Rare diseases affect 1 in 10 Americans. That’s roughly 30 million people and approximately 50 percent of all rare diseases affect children. That’s why hundreds of patients, advocates, regulatory and industry leaders gathered for the fifth annual Global Genes Rare Patient Advocacy Summit on September 22 – 23 in California.
learn more
October 04, 2016

Dohmen experts lead key discussions at MDRP Summit in Chicago

Experts from Financial Services, Market Access and Government Programs at Dohmen Life Science Services (DLSS) participated in the 2016 Medicaid Drug Rebate Program (MDRP) Summit in Chicago, leading important discussions on current and future regulatory challenges.
learn more
September 12, 2016

Dohmen experts to share regulatory and financial insights at upcoming MDRP Summit

Dohmen Life Science Services (DLSS) financial experts will join more than 500 private and public sector leaders at the Medicaid Drug Rebate Program (MDRP) Summit, Sept. 20-22 in Chicago.
learn more
August 23, 2016

Dohmen helps navigate regulatory challenges of combination products

RAPS invited Dohmen Life Science Services (DLSS) experts Eric Floyd, Ph.D., MBA, M.S., Chief Science Officer and President of Compliance Services, and Terry Dagnon, M.S., Senior Vice President of Denver Operations, to share their insights on combination products and regulations.
learn more
August 12, 2016

Dohmen invited to present on regulatory hot topics

Dohmen Life Science Services experts were invited to present on combination products to the Regulatory Affairs Professionals Society (RAPS) Chicago Chapter at AbbVie Inc., North Chicago, Ill. on Aug. 18.
learn more